伊立替康联合卡培他滨治疗晚期结直肠癌的临床观察

The clinical observation of irinotecan combined capecitabine for 60 patients with locally advanced or metastatic colorectal cancer

目的：观察伊立替康（CPT-11）联合卡培他滨（Capecitabine，希罗达）治疗晚期结直肠癌的疗效及毒性反应。方法：从2004年2月-2006年5月对晚期结直肠癌采用CPT-11联合卡培他滨方案化疗。入组患者均经病理组织学证实，且有可测量病灶。具体方案为：CPT-11250mg／m^2 iv，d1；希罗达1250mg／m^2 po，bid，d1-d14。21天为1个周期，化疗2个周期后评价疗效及毒性反应。结果：可评价疗效者60例，其中完全缓解（CR）4例，部分缓解（PR）22例，有效率（RR）为43．3％，稳定（SD）28例（46．7％），进展（PD）6例（10．0％）。临床受益率为83．3％，疼痛缓解率83．3％。肿瘤中位进展时间7．2个月，中位生存期13．8个月。主要毒副反应为迟发性腹泻和中性粒细胞减少，未出现治疗相关性死亡。结论：CPT-11联合卡培他滨方案治疗晚期结直肠癌患者有较好疗效，毒副反应可以接受。

Objective ：To investigate the efficacy and toxicity of irinotecan （ CPT-11 ） combined capecitabine for patients with locally advanced or metastatic colorectal cancer. Methods：From February 2004 to May 2006, 60 evaluable patients with locally advanced or metastatic colorectal cancer based chemotherapy received Irinotecan（250mg/m^2 iv gtt）on day 1 and capecitabine （ 1 250mg/ m2 po bid） on days 1 to 14, the regimen was repeated every 3 weeks and efficacy and toxicity were evaluated after 2 cycles. Results ： In 60 evaluable patients, 4 cases had complete response, 22 cases had partial response, 28 cases had stable disease and 6 eases with progressive disease. The response rate of the whole group was 43.3% and the stability rate was 46. 7%. The clinical response rate was 83.3%. Median time to progression was 7.2 months and median overall survival time was 13.8 months. Dose limiting toxicity was delayed diarrhea and neutropenia. There was no death during the treatment. Conclusion：The regimen CPT-11 combined capecitabine is efficacious and tolerable for locally advanced or metastatic colorectal cancer.